IP Library › Granted Patent US 12,564,629
Granted Patent B2
US 12,564,629 · App. 17/917,987 · Granted Mar 3, 2026

Vaccine to protect against mycoplasma hyopneumoniae

Inventors: Johanna Jacoba Elisabeth Bijlsma (Boxmeer, NL); Maarten Hendrik Witvliet (Boxmeer, NL); Didier Betbeder (Loos, FR)
Assignee: Vaxinano SAS
A61K39/295A61K39/0241A61P31/04A61K2039/522A61K2039/5254A61K2039/545A61K2039/552A61K2039/55555B82Y5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,564,629
App. No.
17/917,987
Granted
Mar 3, 2026
Kind
B2
Abstract

A vaccine comprising nanoparticles in association with a Mycoplasma hyopneumoniae bacterin, wherein the nanoparticles comprise a cationic polysaccharide and an anionic phospholipid.

Claims (14)

1 . A vaccine comprising nanoparticles and a Mycoplasma hyopneumoniae bacterin, wherein the Mycoplasma hyopneumoniae bacterin is associated to the outside of the nanoparticle via non-covalent attachments and wherein the nanoparticles comprises a cationic polysaccharide that is a porous polysaccharide and an anionic phospholipid.

2 . The vaccine according to claim 1 , wherein the anionic phospholipid is selected from diacylphosphatidyl glycerol, diacylphosphatidyl serine and diacylphosphatidyl inositol.

3 . The vaccine according to claim 1 , wherein the cationic polysaccharide is obtainable by reacting crosslinked maltodextrin with glycidyl-trimethylammonium.

4 . The vaccine according to claim 1 , further comprising a pharmaceutically acceptable solvent.

5 . The vaccine according to claim 1 , wherein the vaccine is essentially free of oil and/or aluminium hydroxide and/or saponins and/or carbopol.

6 . A method for the prophylaxis of an infection with Mycoplasma hyopneumoniae in pigs comprising administering an effective amount of the vaccine according to claim 1 .

7 . The method according to claim 6 , wherein the vaccine is administered systemically.

8 . The method according to claim 6 , wherein the vaccine is administered intradermally.

9 . The method according to claim 6 , wherein the vaccine is administered as a single dose.

10 . The method according to claim 6 , for use in the reduction of lung lesions due to the infection with Mycoplasma hyopneumoniae.

11 . A kit of parts comprising a first vaccine, a second vaccine and a leaflet, wherein the first vaccine is a vaccine according to claim 1 and the second vaccine comprises live attenuated porcine reproductive and respiratory syndrome virus (PRRSV).

12 . A combination vaccine comprising a mixture of a first vaccine and a second vaccine, wherein the first vaccine is a vaccine according to claim 1 and the second vaccine comprises live attenuated porcine reproductive and respiratory syndrome virus (PRRSV).

13 . A vial comprising the vaccine according to the combination vaccine of claim 12 .

14 . A vial comprising the vaccine according to claim 1 .

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2026
From: BETBEDER, DIDIER
To: VAXINANO SAS
Reel/Frame 073517/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2025
From: INTERVET INC.; INTERVET INTERNATIONAL B.V.
To: VAXINANO SAS
Reel/Frame 073100/0343 →
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2022
From: BIJLSMA, JOHANNA JACOBA ELISABETH; WITVLIET, MAARTEN HENDRIK
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 061362/0462 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2022
From: INTERVET INTERNATIONAL B.V.
To: INTERVET INC.
Reel/Frame 061362/0735 →
Priority Claims (1)
EP 20170440 · Apr 20, 2020 · regional
Continuity (1)
Related Publication 20230145957A1 · May 11, 2023
References Cited (11)
US 8828929B2 · Matsui · 2014 [cited by applicant]
US 20090304737A1 · Drexler et al. · 2009 [cited by applicant]
EP 2708237A1 · 2014 [cited by applicant]
WO 2014041427A1 · 2014 [cited by applicant]
WO 2017162741A1 · 2017 [cited by applicant]
WO 2018104762A1 · 2018 [cited by applicant]
WO WO2020018429A1 · 2020 [cited by applicant]
Paillard Archibald et al., Positively-Charged, Porous, Polysaccharide Nanoparticles Loaded with Anionic Molecules Behave as ‘Stealth’ Cationic Nanocarriers, Pharmaceutical Research, 2010, 126-133, 27(1). [cited by applicant]
Dimier-Poisson et al., 2015, “Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection,” Biomaterials, 50:164-175. [cited by applicant]
Matthijs et al., 2019, “Systems Immunology Characterization of Novel Vaccine Formulations for Mycoplasma hyopneumoniae Bacterins,” Front Immunol., 10:1087 (19 pages). [cited by applicant]
Karkishchenko, V.N. et al., Pharmacological bases of therapy, Thesaurus: Handbook for doctors and students, Third edition, 7-8, 2018 (English Translation). [cited by applicant]